The public issue is entirely an offer-for-sale (OFS) of up to 21.7 million shares by the promoters and other shareholders to the tune of around ₹1,800 crore, said bankers. The company operates under the “Blue Jet” brand offering niche products targeted at innovator pharmaceutical companies and multinational generic pharmaceutical companies.
India top market for me, but regulatory red tape holding it back: Mark Mobius
Mark Mobius reaffirmed his bullish stance on Indian equities, despite geopolitical tensions with Pakistan. He criticized bureaucratic hurdles slowing foreign investments and urged investors to
May 15, 2025